|1.||van Midwoud, Paul M: 1 article (11/2013)|
|2.||Sturla, Shana J: 1 article (11/2013)|
|3.||McMorris, Trevor C: 1 article (02/2010)|
|4.||Kelner, Michael J: 1 article (02/2010)|
|5.||Staake, Michael D: 1 article (02/2010)|
|6.||Alisala, Kashinatham: 1 article (02/2010)|
|7.||Chimmani, Ramesh: 1 article (02/2010)|
|8.||Banda, Gangadasu: 1 article (02/2010)|
|9.||Waters, Stephen J: 1 article (01/2010)|
|10.||Van Laar, Emily S: 1 article (01/2010)|
01/01/1998 - "Acylfulvene derivatives demonstrate marked efficacy in xenograft carcinoma models as compared with the parent illudin compounds. "
01/01/1998 - "The prototype acylfulvene analog retained selective histiospecific toxicity towards myeloid leukemia and various carcinoma cell lines. "
05/01/1998 - "A new semisynthetic derivative, MGI 114 (NSC 683,863, 6-hydroxymethyl-acylfulvene, HMAF), is markedly effective in a variety of lung, breast and colon carcinoma xenograft models. "
11/01/1995 - "Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells."
01/01/1999 - "One acylfulvene derivative, MGI 114 (HMAF), demonstrates marked efficacy in xenograft carcinoma models when compared to the parent acylfulvene or related illudin compounds. "
|2.||Stomach Neoplasms (Stomach Cancer)
|3.||Colonic Neoplasms (Colon Cancer)
02/11/2010 - "Illudins have a low therapeutic index, but acylfulvene derivatives display potent in vivo antitumor activity against a variety of multidrug resistant tumors. "
01/01/1998 - "Analysis of cellular accumulation of acylfulvene into tumor cells revealed a markedly higher Vmax for tumor cells, and a lower Vd for diffusion accumulation into other cells. "
11/01/1995 - "One analogue, the parent illudofulvene-derivative called Acylfulvene, inhibited xenograft primary tumor growth and prolonged life span of tumor-bearing animals when administered i.p. "
01/01/2010 - "Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene."
01/01/1999 - "The addition of a single methylhydroxyl group to acylfulvene to produce MGI 114 results in a marked increase in cytotoxicity in vitro towards tumor cells as demonstrated by the reduction in IC50 values. "
|2.||A-Form DNA (A-DNA)
|3.||DNA (Deoxyribonucleic Acid)
|5.||7-hydroxystaurosporine (UCN 01)
|7.||Galectin 1 (LGALS1)
|9.||Adenocarcinoma of lung
|1.||Heterologous Transplantation (Xenotransplantation)